Effect of Prostaglandin E2 and Prostaglandin F2α on Cyclooxygenase-1 and Cyclooxygenase-2 Expression in Lipopolysaccharide-treated Bovine Endometrial Epithelial Cells

This study was aimed to clarify the effects of prostaglandin E₂ (PGE₂) and prostaglandin F_2α (PGF_2α) on cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) mRNA and protein expression in bovine endometrial epithelial cells. Primary and generation of bovine endometrial epithelial cells were cultured, and the fourth generation cells with 1×10⁶/hole vaccination were pretreated with PGE₂, PGF_2α, PGE₂+PGF_2α (10^-7 mol/L) for 24 h, respectively, following treatment with 100 ng/mL LPS for 4, 8 and 12 h, respectively. The expression of COX-1 and COX-2 mRNA and protein were measured by Real-time quantitative PCR and Western blotting methods. The results showed that compare with control group, the expression of COX-1 mRNA was significantly up-regulated after PGE₂ treatment at 4, 8 and 12 h, the expression of COX-2 mRNA was significantly up-regulated at 4 and 12 h, the COX-1 and COX-2 proteins were significantly up-regulated after PGE₂ treatment (P<0.05). Compare with control group, the expression of COX-1 mRNA was significantly dowm-regulated by LPS treatment at 8 and 12 h, while the COX-1 protein was not affected, the expression of COX-2 mRNA was significantly up-regulated by LPS treatment at 4, 8 and 12 h,and COX-2 protein was significantly up-regulated after LPS treatment (P<0.05). Compared with LPS treatment group, the expression of COX-1 and COX-2 mRNA were significantly up-regulated after LPS+PGE₂ treatment at 8 and 12 h, and the COX-1 and COX-2 protein were significantly up-regulated (P<0.05). There were no significant effect on the expression of COX-1 and COX-2 mRNA after PGF_2α and LPS present or absent treatment (P>0.05), only significantly increased the expression of COX-1 mRNA after PGF_2α treatment at 8 and 12 h (P<0.05). The expression of COX-1 and COX-2 mRNA were induced after PGE₂ and PGF_2α combination treatment group compared with that in PGE₂, PGF_2α and LPS treatment groups.